Published August 1, 2013 | Version v1
Journal article

Low-Dose Radiation Therapy (2 Gy × 2) in the Treatment of Orbital Lymphoma

  • 1. Department of Radiation Oncology, Stanford University, Stanford, California (United States)
  • 2. Vaccine Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland (United States)
  • 3. Department of Internal Medicine, University of California-Los Angeles Olive View, Sylmar, California (United States)

Description

Purpose: Low-dose radiation has become increasingly used in the management of indolent non-Hodgkin lymphoma (NHL), but has not been studied specifically for cases of ocular adnexal involvement. The objective of this study is to investigate the effectiveness of low-dose radiation in the treatment of NHL of the ocular adnexa. Methods and Materials: We reviewed the records of 20 NHL patients with 27 sites of ocular adnexal involvement treated with low-dose radiation consisting of 2 successive fractions of 2 Gy at our institution between 2005 and 2011. The primary endpoint of this study is freedom from local relapse (FFLR). Results: At a median follow-up time of 26 months (range 7-92), the overall response rate for the 27 treated sites was 96%, with a complete response (CR) rate of 85% (n=23) and a partial response rate of 11% (n=3). Among all treated sites with CR, the 2-year FFLR was 100%, with no in-treatment field relapses. The 2-year freedom from regional relapse rate was 96% with 1 case of relapse within the ipsilateral orbit (outside of the treatment field). This patient underwent additional treatment with low-dose radiation of 4 Gy to the area of relapse achieving a CR and no evidence of disease at an additional 42 months of follow-up. Orbital radiation was well tolerated with only mild acute side effects (dry eye, conjunctivitis, transient periorbital edema) in 30% of treated sites without any reports of long-term toxicity. Conclusions: Low-dose radiation with 2 Gy × 2 is effective and well tolerated in the treatment of indolent NHL of the ocular adnexa with high response rates and durable local control with the option of reirradiation in the case of locoregional relapse

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2013.04.035

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2013.04.035;
PII
S0360-3016(13)00464-1;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
86
Journal Issue
5
Journal Page Range
p. 930-935
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
45089069
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
EDEMA; LYMPHOMAS; PATIENTS; RADIATION DOSES; RADIOTHERAPY; REVIEWS; SIDE EFFECTS; TOXICITY
Descriptors DEC
DISEASES; DOCUMENT TYPES; DOSES; IMMUNE SYSTEM DISEASES; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; PATHOLOGICAL CHANGES; RADIOLOGY; SYMPTOMS; THERAPY

Optional Information

Copyright
Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.